- Home
- TLPH vs PMCB Comparison
TLPH vs PMCB Comparison
Compare TLPH & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | PMCB |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 5.3M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLPH | PMCB |
|---|---|---|
| Price | $1.20 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 355.3K | ★ 9.9M |
| Earning Date | 11-12-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $28,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,267.20 | N/A |
| P/E Ratio | ★ N/A | $162.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.63 |
| 52 Week High | $1.57 | $1.90 |
Technical Indicators
Market Signals| Indicator | TLPH | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 56.81 |
| Support Level | $1.20 | $0.71 |
| Resistance Level | $1.33 | $1.51 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 7.50 | 44.32 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.